Last reviewed · How we verify
Fulvestrant Injectable Product (fulvestrant-injectable-product)
Fulvestrant Injectable Product (generic name: fulvestrant-injectable-product) is a estrogen receptor degrader drug developed by Pfizer. It is currently FDA-approved for Advanced breast cancer in postmenopausal women with disease progression following prior therapy, Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy, Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting.
Fulvestrant Injectable Product is a marketed drug by Pfizer Inc. It is used for advanced breast cancer in postmenopausal women with disease progression following prior therapy. The drug is also indicated for hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy or endocrine therapy and chemotherapy. There are 57 trials and 0 publications available for this drug. The revenue and mechanism of action are not specified. As a marketed drug, it has commercial significance and pipeline developments.
At a glance
| Generic name | fulvestrant-injectable-product |
|---|---|
| Sponsor | Pfizer |
| Drug class | estrogen receptor degrader |
| Target | estrogen receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Advanced breast cancer in postmenopausal women with disease progression following prior therapy
- Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy
- Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting
Common side effects
Drug interactions
- Warfarin
- Tamoxifen
- Estrogen-containing products
- Aromatase inhibitors
- CYP3A4 inhibitors
- CYP3A4 inducers
Key clinical trials
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations (PHASE1)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- SNV4818 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Fulvestrant With or Without Ganetespib in HR+ Breast Cancer (PHASE2)
- Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers (PHASE1)
- Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer (PHASE2)
- A Study of Single Dose of BL0175 in Postmenopausal Women (PHASE1)
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fulvestrant Injectable Product CI brief — competitive landscape report
- Fulvestrant Injectable Product updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Fulvestrant Injectable Product
What is Fulvestrant Injectable Product?
What is Fulvestrant Injectable Product used for?
Who makes Fulvestrant Injectable Product?
What is the generic name of Fulvestrant Injectable Product?
What drug class is Fulvestrant Injectable Product in?
What development phase is Fulvestrant Injectable Product in?
What does Fulvestrant Injectable Product target?
Related
- Drug class: All estrogen receptor degrader drugs
- Target: All drugs targeting estrogen receptor
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced breast cancer in postmenopausal women with disease progression following prior therapy
- Indication: Drugs for Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy
- Indication: Drugs for Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing